A Phase 2 interventional study of Bevacizumab and Carboplatin in Non-Small-Cell Lung Carcinoma and Adenocarcinoma, sponsored by Pfizer. Completed at 44 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-08.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 53rd largest by enrollment of the 136 interventional ones that give a count, is one of 8 that started in 2008, is one of 45 in phase 2, and was the 31st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, China and 8 more countries
Ages 18+
Pfizer · Sites in United States, China, France and 6 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 69 · Phase 2 58 · Phase 3 18 · Phase 4 4
First in 1999; this study’s year is marked. 8 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 118 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 79 across the 136 interventional studies, 97 across the 17 observational. Of the 123 that completed or were terminated, 70 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Carcinoma, Non-Small-Cell Lung by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07567352PfizerA Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment | 2027-03-01 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
| NCT05538130PfizerA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | 2027-08-31 |
| NCT05355701PfizerA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bevacizumab will be administered in combination with carboplatin and paclitaxel.
Drug: Bevacizumab · Drug: Carboplatin · Drug: Paclitaxel
AG-013736 will be administered in combination with carboplatin and paclitaxel.
Drug: AG-013736 (axitinib) · Drug: Carboplatin · Drug: Paclitaxel
Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
Also known as: Avastin
Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
Also known as: axitinib Taxol
Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.
Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
Progression Free Survival (PFS)
Time in months from start of study treatment to first randomization date of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
Time frame: Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years
Overall Survival (OS)
Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the first randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
Time frame: Baseline, every 6 weeks until death or bimonthly after final study visit (up to 2.75 years)
Percentage of Participants With Objective Response (OR)
OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR: disappearance of all lesions (target and/or non target) and no appearance of new lesions. PR: at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, without progression of non target lesions and no appearance of new lesions.
Time frame: Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years
Duration of Response (DR)
Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years
Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736)
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Pre-dose, 1 to 2 hours post-dose on Cycle 2 of Day 1 and Cycle 3 of Day 1
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhoea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.
Time frame: Day (D) 1 of every cycle (C) then every 3 weeks until final study visit (up to 2.75 years)
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnoea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.
Time frame: Day 1 of every cycle then every 3 weeks until final study visit (up to 2.75 years)
Percentage of Participants by Ribonucleic Acid (RNA) Expression Profile in Whole Blood
RNA expression profiles of genes which were associated with tumor growth, angiogenesis and metastases were collected and correlated with efficacy.
Time frame: Baseline, C1 D1, C1 D15, C2 D1, C3 D1, C4 D1 and C5 D1
Circulating Endothelial Cells (CEC) in Blood: Total CEC
Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.
Time frame: Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1
Circulating Endothelial Cells (CEC) in Blood
Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.
Time frame: Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1
Plasma Concentration of Soluble Proteins
Plasma concentrations of soluble proteins (soluble- stem-cell factor receptor (sKIT) vascular endothelial growth factor \[VEGF\], and vascular endothelial growth factor receptor-2 \[VEGFR2\], VEGFR3) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.
Time frame: Baseline, C1D1, C1D15, C2D1, C3D1, C4D1, C5D1, C7D1, C9D1 and C11D1
Plasma Concentration Change in the Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Genotype
UGT1A1 an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites.
Time frame: Baseline (Day 1 of Cycle 1)
| Milestone | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Started | 58 | 60 |
| Treated | 58 | 59 |
| Completed | 0 | 0 |
| Not completed | 58 | 60 |
| Withdrew: Death | 45 | 46 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Terminated by sponsor | 8 | 6 |
| Withdrew: Objective progression or relapse | 0 | 1 |
| Withdrew: Randomized but not treated | 0 | 1 |
| Withdrew: Other | 2 | 3 |
Time in months from start of study treatment to first randomization date of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
| Months | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Progression Free Survival (PFS) | 5.7 (4.1 to 7.5) | 6.1 (4.2 to 8.7) |
Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the first randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
| Months | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Overall Survival (OS) | 10.6 (7.5 to 16.4) | 13.3 (10.4 to 17.6) |
OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR: disappearance of all lesions (target and/or non target) and no appearance of new lesions. PR: at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, without progression of non target lesions and no appearance of new lesions.
| Percentage of participants | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Percentage of Participants With Objective Response (OR) | 29.3 (18.1 to 42.7) | 43.3 (30.6 to 56.8) |
Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| Months | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Duration of Response (DR) | 4.4 (4.2 to 6.7) | 7.0 (4.8 to 8.3) |
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Results for this outcome have not been posted.
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhoea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.
| Units on a scale | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Physical functioning (PF): Baseline (n=58, 59) | 66.29 ± 22.04 | 75.00 ± 22.21 |
| PF: C2 D1 (n=51, 53) | 67.45 ± 23.48 | 75.47 ± 20.24 |
| PF: C3 D1 (n=45, 47) | 65.78 ± 24.40 | 78.16 ± 18.43 |
| PF: C4 D1 (n=37, 48) | 67.88 ± 20.01 | 73.78 ± 19.14 |
| PF: C5 D1 (n=34, 38) | 61.18 ± 24.09 | 75.09 ± 16.38 |
| PF: C6 D1 (n=31, 33) | 65.86 ± 19.17 | 73.94 ± 18.66 |
| PF: C7 D1 (n=27, 30) | 66.42 ± 22.15 | 74.89 ± 18.67 |
| PF: C8 D1 (n=22, 28) | 67.27 ± 22.44 | 77.14 ± 18.98 |
| PF: C9 D1 (n=18, 23) | 66.30 ± 27.77 | 74.57 ± 19.02 |
| PF: C10 D1 (n=17, 20) | 68.63 ± 25.36 | 81.33 ± 14.92 |
| PF: C11 D1 (n=15, 19) | 60.67 ± 23.58 | 78.25 ± 16.00 |
| PF: C12 D1 (n=10, 17) | 71.33 ± 20.86 | 78.43 ± 19.65 |
| PF: C13 D1 (n=8, 14) | 66.67 ± 25.94 | 79.05 ± 21.22 |
| PF: End of treatment (EOT) (n=27, 38) | 62.96 ± 21.11 | 64.91 ± 24.83 |
| Role functioning: Baseline (n=58, 58) | 60.92 ± 31.15 | 60.63 ± 31.79 |
| Role functioning: C2 D1 (n=51, 53) | 64.38 ± 31.98 | 65.41 ± 29.02 |
| Role functioning: C3 D1 (n=45, 47) | 58.15 ± 34.01 | 70.92 ± 28.55 |
| Role functioning: C4 D1 (n=37, 48) | 67.12 ± 26.49 | 67.36 ± 25.02 |
| Role functioning: C5 D1 (n=34, 38) | 57.35 ± 29.64 | 66.23 ± 29.12 |
| Role functioning: C6 D1 (n=31, 33) | 62.90 ± 30.34 | 67.68 ± 29.15 |
| Role functioning: C7 D1 (n=28, 30) | 55.36 ± 32.41 | 63.89 ± 27.01 |
| Role functioning: C8 D1 (n=22, 28) | 65.15 ± 29.05 | 71.43 ± 19.70 |
| Role functioning: C9 D1 (n=18, 23) | 63.89 ± 37.60 | 70.29 ± 18.77 |
| Role functioning: C10 D1 (n=17, 20) | 66.67 ± 28.87 | 70.83 ± 20.14 |
| Role functioning: C11 D1 (n=15, 19) | 60.00 ± 29.41 | 71.93 ± 21.55 |
| Role functioning: C12 D1 (n=10, 17) | 75.00 ± 21.15 | 70.59 ± 21.67 |
| Role functioning: C13 D1 (n=8, 14) | 62.50 ± 33.04 | 80.95 ± 20.52 |
| Role functioning: EOT (n=27, 38) | 57.41 ± 32.47 | 57.90 ± 31.18 |
| Emotional functioning: Baseline (n=57, 57) | 69.74 ± 23.45 | 63.74 ± 27.44 |
| Emotional functioning: C2 D1 (n=50, 53) | 78.33 ± 21.76 | 73.64 ± 22.81 |
| Emotional functioning: C3 D1 (n=45, 48) | 75.19 ± 21.36 | 78.76 ± 20.69 |
| Emotional functioning: C4 D1 (n=37, 48) | 75.75 ± 20.17 | 76.04 ± 23.23 |
| Emotional functioning: C5 D1 (n=32, 38) | 77.60 ± 18.38 | 78.51 ± 21.37 |
| Emotional functioning: C6 D1 (n=29, 32) | 78.74 ± 18.97 | 77.35 ± 23.40 |
| Emotional functioning: C7 D1 (n=28, 30) | 78.57 ± 22.62 | 79.45 ± 20.50 |
| Emotional functioning: C8 D1 (n=22, 28) | 77.65 ± 19.14 | 81.25 ± 18.09 |
| Emotional functioning: C9 D1 (n=18, 23) | 74.07 ± 19.78 | 78.50 ± 23.39 |
| Emotional functioning: C10 D1 (n=17, 20) | 77.94 ± 18.85 | 78.33 ± 13.36 |
| Emotional functioning: C11 D1 (n=15, 19) | 70.00 ± 21.32 | 82.46 ± 18.61 |
| Emotional functioning: C12 D1 (n=10, 17) | 74.17 ± 27.90 | 77.45 ± 20.57 |
| Emotional functioning: C13 D1 (n=8, 14) | 77.08 ± 22.60 | 83.93 ± 14.79 |
| Emotional functioning: EOT (n=27, 38) | 68.52 ± 26.39 | 70.18 ± 25.60 |
| Cognitive Functioning: Baseline (n=57, 57) | 80.12 ± 24.28 | 83.33 ± 19.16 |
| Cognitive Functioning: C2 D1 (n=50, 53) | 84.00 ± 20.47 | 84.28 ± 21.29 |
| Cognitive Functioning: C3 D1 (n=45, 48) | 85.19 ± 22.81 | 85.42 ± 20.81 |
| Cognitive Functioning: C4 D1 (n=37, 48) | 84.68 ± 18.99 | 82.64 ± 20.03 |
| Cognitive Functioning: C5 D1 (n=32, 38) | 84.37 ± 19.83 | 83.33 ± 24.51 |
| Cognitive Functioning: C6 D1 (n=29, 32) | 86.78 ± 18.03 | 81.25 ± 21.06 |
| Cognitive Functioning: C7 D1 (n=28, 30) | 79.76 ± 19.43 | 85.56 ± 18.94 |
| Cognitive Functioning: C8 D1 (n=22, 28) | 89.39 ± 17.48 | 88.69 ± 17.00 |
| Cognitive Functioning: C9 D1 (n=18, 23) | 84.26 ± 15.63 | 86.23 ± 20.51 |
| Cognitive Functioning: C10 D1 (n=17, 20) | 88.23 ± 12.86 | 90.00 ± 13.68 |
| Cognitive Functioning: C11 D1 (n=15, 19) | 82.22 ± 18.33 | 85.96 ± 18.64 |
| Cognitive Functioning: C12 D1 (n=10, 17) | 90.00 ± 14.05 | 87.25 ± 20.01 |
| Cognitive Functioning: C13 D1 (n=8, 14) | 85.42 ± 13.91 | 95.24 ± 12.10 |
| Cognitive Functioning: EOT (n=27, 38) | 77.78 ± 23.57 | 78.95 ± 22.82 |
| Social functioning: Baseline (n=57, 57) | 71.35 ± 27.59 | 65.50 ± 32.25 |
| Social functioning: C2 D1 (n=50, 52) | 69.67 ± 30.06 | 75.32 ± 25.24 |
| Social functioning: C3 D1 (n=45, 48) | 71.11 ± 27.62 | 74.65 ± 24.79 |
| Social functioning: C4 D1 (n=37, 48) | 73.42 ± 24.99 | 71.53 ± 29.77 |
| Social functioning: C5 D1 (n=32, 38) | 65.10 ± 26.22 | 75.88 ± 27.04 |
| Social functioning: C6 D1 (n=29, 32) | 70.11 ± 26.49 | 71.88 ± 26.92 |
| Social functioning: C7 D1 (n=28, 30) | 64.88 ± 32.50 | 72.22 ± 23.71 |
| Social functioning: C8 D1 (n=22, 28) | 71.97 ± 24.87 | 72.02 ± 24.45 |
| Social functioning: C9 D1 (n=18, 23) | 74.07 ± 29.83 | 81.16 ± 16.13 |
| Social functioning: C10 D1 (n=17, 20) | 72.55 ± 32.24 | 79.17 ± 20.14 |
| Social functioning: C11 D1 (n=15, 19) | 66.67 ± 28.17 | 78.95 ± 16.52 |
| Social functioning: C12 D1 (n=10, 17) | 71.67 ± 20.86 | 80.39 ± 20.61 |
| Social functioning: C13 D1 (n=8, 14) | 56.25 ± 28.08 | 80.95 ± 18.32 |
| Social functioning: EOT (n=27, 38) | 69.14 ± 26.03 | 65.79 ± 26.83 |
| Fatigue: Baseline (n=57, 58) | 40.45 ± 23.94 | 38.89 ± 28.02 |
| Fatigue: C2 D1 (n=51, 53) | 43.57 ± 21.98 | 36.48 ± 25.26 |
| Fatigue: C3 D1 (n=45, 47) | 47.41 ± 22.77 | 33.80 ± 19.38 |
| Fatigue: C4 D1 (n=37, 48) | 42.34 ± 19.22 | 37.85 ± 19.40 |
| Fatigue: C5 D1 (n=34, 38) | 44.61 ± 21.73 | 36.84 ± 22.83 |
| Fatigue: C6 D1 (n=31, 33) | 45.16 ± 23.65 | 33.50 ± 21.45 |
| Fatigue: C7 D1 (n=28, 30) | 47.82 ± 27.27 | 40.74 ± 21.11 |
| Fatigue: C8 D1 (n=22, 28) | 44.95 ± 24.84 | 32.14 ± 20.14 |
| Fatigue: C9 D1 (n=18, 23) | 40.12 ± 29.80 | 28.98 ± 20.03 |
| Fatigue: C10 D1 (n=17, 20) | 41.83 ± 25.62 | 30.00 ± 19.78 |
| Fatigue: C11 D1 (n=15, 19) | 47.78 ± 32.52 | 28.07 ± 14.52 |
| Fatigue: C12 D1 (n=10, 17) | 37.78 ± 19.74 | 29.41 ± 18.82 |
| Fatigue: C13 D1 (n=8, 14) | 50.00 ± 24.49 | 26.19 ± 22.05 |
| Fatigue: EOT (n=27, 38) | 51.03 ± 24.51 | 43.13 ± 27.57 |
| Nausea and vomiting: Baseline (n=57, 59) | 8.77 ± 17.85 | 9.89 ± 21.91 |
| Nausea and vomiting: C2 D1 (n=51, 53) | 7.19 ± 13.02 | 5.35 ± 12.56 |
| Nausea and vomiting: C3 D1 (n=45, 47) | 11.11 ± 17.77 | 5.67 ± 11.67 |
| Nausea and vomiting: C4 D1 (n=37, 48) | 10.81 ± 16.77 | 7.29 ± 11.86 |
| Nausea and vomiting: C5 D1 (n=34, 38) | 13.24 ± 21.63 | 7.46 ± 14.34 |
| Nausea and vomiting: C6 D1 (n=31, 33) | 13.44 ± 21.26 | 10.61 ± 17.59 |
| Nausea and vomiting: C7 D1 (n=28, 30) | 15.48 ± 22.65 | 9.44 ± 14.31 |
| Nausea and vomiting: C8 D1 (n=22, 28) | 14.40 ± 22.00 | 5.95 ± 12.18 |
| Nausea and vomiting: C9 D1 (n=18, 23) | 9.26 ± 13.06 | 5.07 ± 20.98 |
| Nausea and vomiting: C10 D1 (n=17, 20) | 11.77 ± 15.33 | 8.33 ± 16.67 |
| Nausea and vomiting: C11 D1 (n=15, 19) | 14.45 ± 17.67 | 5.26 ± 9.71 |
| Nausea and vomiting: C12 D1 (n=10, 17) | 15.00 ± 16.57 | 6.68 ± 14.50 |
| Nausea and vomiting: C13 D1 (n=8, 14) | 12.50 ± 17.25 | 5.95 ± 14.03 |
| Nausea and vomiting: EOT (n=27, 38) | 16.05 ± 22.40 | 7.90 ± 14.36 |
| Pain: Baseline (n=57, 59) | 31.29 ± 31.82 | 35.31 ± 30.02 |
| Pain: C2 D1 (n=51, 53) | 29.74 ± 29.87 | 28.30 ± 29.16 |
| Pain: C3 D1 (n=45, 48) | 30.00 ± 27.43 | 18.75 ± 18.07 |
| Pain: C4 D1 (n=37, 48) | 26.58 ± 18.62 | 25.35 ± 27.29 |
| Pain: C5 D1 (n=34, 38) | 25.00 ± 18.91 | 24.12 ± 24.72 |
| Pain: C6 D1 (n=31, 33) | 31.18 ± 18.63 | 25.25 ± 28.90 |
| Pain: C7 D1 (n=28, 30) | 28.57 ± 28.99 | 27.22 ± 26.07 |
| Pain: C8 D1 (n=22, 28) | 28.03 ± 25.91 | 22.62 ± 23.66 |
| Pain: C9 D1 (n=18, 23) | 33.33 ± 22.14 | 27.54 ± 31.22 |
| Pain: C10 D1 (n=17, 20) | 30.39 ± 26.51 | 24.17 ± 24.47 |
| Pain: C11 D1 (n=15, 19) | 43.33 ± 28.03 | 18.42 ± 21.44 |
| Pain: C12 D1 (n=10, 17) | 35.00 ± 21.45 | 23.53 ± 29.50 |
| Pain: C13 D1 (n=8, 14) | 35.42 ± 24.30 | 16.67 ± 21.68 |
| Pain: EOT (n=27, 38) | 38.27 ± 33.27 | 34.65 ± 30.36 |
| Dyspnoea: Baseline (n=56, 58) | 32.74 ± 30.15 | 36.21 ± 33.21 |
| Dyspnoea: C2 D1 (n=51, 52) | 32.03 ± 28.25 | 24.36 ± 31.04 |
| Dyspnoea: C3 D1 (n=45, 47) | 38.52 ± 28.39 | 19.15 ± 23.82 |
| Dyspnoea: C4 D1 (n=37, 48) | 33.33 ± 30.43 | 21.53 ± 25.25 |
| Dyspnoea: C5 D1 (n=34, 38) | 36.27 ± 33.20 | 23.68 ± 27.84 |
| Dyspnoea: C6 D1 (n=31, 33) | 36.56 ± 31.45 | 20.20 ± 23.48 |
| Dyspnoea: C7 D1 (n=28, 30) | 38.09 ± 31.05 | 21.11 ± 20.50 |
| Dyspnoea: C8 D1 (n=22, 28) | 27.27 ± 28.43 | 16.67 ± 19.24 |
| Dyspnoea: C9 D1 (n=18, 23) | 25.93 ± 33.44 | 21.74 ± 21.58 |
| Dyspnoea: C10 D1 (n=17, 20) | 27.45 ± 31.70 | 18.33 ± 17.01 |
| Dyspnoea: C11 D1 (n=15, 19) | 37.78 ± 33.01 | 17.54 ± 23.22 |
| Dyspnoea: C12 D1 (n=10, 17) | 23.33 ± 27.44 | 21.57 ± 23.40 |
| Dyspnoea: C13 D1 (n=8, 14) | 37.50 ± 37.53 | 19.05 ± 17.12 |
| Dyspnoea: EOT (n=27, 38) | 35.80 ± 27.62 | 33.33 ± 33.78 |
| Insomnia: Baseline (n=57, 58) | 46.20 ± 33.19 | 37.93 ± 31.50 |
| Insomnia: C2 D1 (n=51, 53) | 36.60 ± 36.06 | 28.30 ± 33.59 |
| Insomnia: C3 D1 (n=45, 47) | 30.37 ± 33.20 | 29.08 ± 33.06 |
| Insomnia: C4 D1 (n=37, 48) | 24.32 ± 26.81 | 27.08 ± 28.89 |
| Insomnia: C5 D1 (n=34, 38) | 28.43 ± 24.80 | 23.68 ± 31.87 |
| Insomnia: C6 D1 (n=31, 33) | 24.73 ± 25.77 | 24.24 ± 29.19 |
| Insomnia: C7 D1 (n=28, 30) | 23.81 ± 28.48 | 25.55 ± 24.26 |
| Insomnia: C8 D1 (n=22, 28) | 21.21 ± 26.32 | 19.05 ± 23.00 |
| Insomnia: C9 D1 (n=18, 23) | 25.93 ± 31.43 | 23.19 ± 27.40 |
| Insomnia: C10 D1 (n=17, 20) | 27.45 ± 26.97 | 20.00 ± 25.13 |
| Insomnia: C11 D1 (n=15, 19) | 33.33 ± 28.17 | 22.81 ± 24.97 |
| Insomnia: C12 D1 (n=10, 17) | 26.67 ± 21.08 | 23.53 ± 28.30 |
| Insomnia: C13 D1 (n=8, 14) | 12.50 ± 17.25 | 16.67 ± 17.29 |
| Insomnia: EOT (n=27, 37) | 28.39 ± 27.28 | 36.94 ± 30.21 |
| Loss of appetite: Baseline (n=57, 59) | 29.82 ± 28.65 | 31.64 ± 34.14 |
| Loss of appetite: C2 D1 (n=51, 53) | 23.53 ± 26.91 | 20.75 ± 29.40 |
| Loss of appetite: C3 D1 (n=44, 47) | 33.33 ± 32.94 | 17.02 ± 25.89 |
| Loss of appetite: C4 D1 (n=37, 48) | 26.13 ± 26.22 | 23.61 ± 27.47 |
| Loss of appetite: C5 D1 (n=34, 38) | 30.39 ± 33.20 | 21.05 ± 29.43 |
| Loss of appetite: C6 D1 (n=31, 33) | 27.96 ± 31.15 | 23.23 ± 26.98 |
| Loss of appetite: C7 D1 (n=28, 30) | 39.29 ± 34.01 | 24.44 ± 23.05 |
| Loss of appetite: C8 D1 (n=22, 28) | 36.36 ± 28.93 | 19.05 ± 21.14 |
| Loss of appetite: C9 D1 (n=18, 23) | 31.48 ± 26.75 | 13.04 ± 24.08 |
| Loss of appetite: C10 D1 (n=17, 20) | 39.22 ± 31.70 | 20.00 ± 25.13 |
| Loss of appetite: C11 D1 (n=15, 19) | 33.33 ± 35.64 | 15.79 ± 17.10 |
| Loss of appetite: C12 D1 (n=10, 17) | 16.67 ± 23.57 | 23.53 ± 30.65 |
| Loss of appetite: C13 D1 (n=8, 14) | 29.17 ± 21.36 | 16.67 ± 28.49 |
| Loss of appetite: EOT (n=27, 38) | 39.51 ± 34.64 | 37.72 ± 33.93 |
| Constipation: Baseline (n=56, 57) | 15.48 ± 23.75 | 21.05 ± 31.89 |
| Constipation: C2 D1 (n=50, 53) | 21.33 ± 28.38 | 20.13 ± 26.43 |
| Constipation: C3 D1 (n=45, 47) | 18.52 ± 24.16 | 14.89 ± 23.88 |
| Constipation: C4 D1 (n=36, 48) | 18.52 ± 26.96 | 13.19 ± 21.46 |
| Constipation: C5 D1 (n=32, 38) | 18.75 ± 22.30 | 21.05 ± 27.31 |
| Constipation: C6 D1 (n=28, 33) | 22.62 ± 25.75 | 19.19 ± 28.90 |
| Constipation: C7 D1 (n=28, 30) | 25.00 ± 26.64 | 7.78 ± 14.34 |
| Constipation: C8 D1 (n=22, 28) | 19.70 ± 19.68 | 2.38 ± 8.74 |
| Constipation: C9 D1 (n=18, 23) | 9.26 ± 19.15 | 5.80 ± 12.92 |
| Constipation: C10 D1 (n=17, 20) | 17.65 ± 20.81 | 5.00 ± 12.21 |
| Constipation: C11 D1 (n=15, 19) | 22.22 ± 20.57 | 8.77 ± 18.73 |
| Constipation: C12 D1 (n=10, 17) | 20.00 ± 23.31 | 5.88 ± 17.62 |
| Constipation: C13 D1 (n=8, 14) | 16.67 ± 25.20 | 4.76 ± 12.10 |
| Constipation: EOT (n=27, 38) | 20.99 ± 29.45 | 14.03 ± 24.05 |
| Diarrhoea: Baseline (n=55, 57) | 6.67 ± 17.45 | 5.85 ± 14.26 |
| Diarrhoea: C2 D1 (n=50, 53) | 11.33 ± 17.31 | 10.06 ± 21.27 |
| Diarrhoea: C3 D1 (n=45, 48) | 15.55 ± 18.26 | 9.72 ± 21.70 |
| Diarrhoea: C4 D1 (n=37, 47) | 13.51 ± 19.97 | 5.67 ± 12.66 |
| Diarrhoea: C5 D1 (n=32, 38) | 22.92 ± 32.17 | 7.89 ± 18.07 |
| Diarrhoea: C6 D1 (n=29, 32) | 21.84 ± 28.56 | 10.42 ± 19.74 |
| Diarrhoea: C7 D1 (n=28, 30) | 16.67 ± 26.45 | 11.11 ± 15.98 |
| Diarrhoea: C8 D1 (n=22, 28) | 24.24 ± 31.17 | 4.76 ± 11.88 |
| Diarrhoea: C9 D1 (n=18, 23) | 27.78 ± 28.58 | 5.80 ± 12.92 |
| Diarrhoea: C10 D1 (n=17, 20) | 23.53 ± 30.65 | 10.00 ± 19.04 |
| Diarrhoea: C11 D1 (n=15, 19) | 31.11 ± 34.43 | 0.00 ± 0.00 |
| Diarrhoea: C12 D1 (n=10, 17) | 43.33 ± 16.10 | 0.00 ± 0.00 |
| Diarrhoea: C13 D1 (n=8, 14) | 33.33 ± 25.20 | 7.14 ± 14.19 |
| Diarrhoea: EOT (n=27, 38) | 23.46 ± 28.96 | 3.51 ± 12.94 |
| Financial difficulties: Baseline (n=56, 57) | 22.62 ± 31.85 | 21.64 ± 27.09 |
| Financial difficulties: C2 D1 (n=49, 53) | 21.77 ± 31.59 | 20.12 ± 27.22 |
| Financial difficulties: C3 D1 (n=45, 48) | 25.93 ± 30.89 | 18.05 ± 23.78 |
| Financial difficulties: C4 D1 (n=37, 48) | 21.62 ± 27.46 | 20.83 ± 30.46 |
| Financial difficulties: C5 D1 (n=32, 38) | 26.04 ± 30.21 | 21.05 ± 28.39 |
| Financial difficulties: C6 D1 (n=29, 32) | 26.44 ± 28.70 | 20.83 ± 29.02 |
| Financial difficulties: C7 D1 (n=28, 30) | 26.19 ± 31.89 | 26.67 ± 30.83 |
| Financial difficulties: C8 D1 (n=21, 28) | 28.57 ± 35.41 | 21.43 ± 32.98 |
| Financial difficulties: C9 D1 (n=18, 23) | 27.78 ± 36.60 | 17.39 ± 29.93 |
| Financial difficulties: C10 D1 (n=17, 19) | 27.45 ± 33.82 | 24.56 ± 33.04 |
| Financial difficulties: C11 D1 (n=15, 19) | 20.00 ± 30.34 | 19.30 ± 27.92 |
| Financial difficulties: C12 D1 (n=10, 17) | 13.33 ± 23.31 | 17.65 ± 26.66 |
| Financial difficulties: C13 D1 (n=8, 14) | 20.83 ± 35.36 | 16.67 ± 28.49 |
| Financial difficulties: EOT (n=27, 37) | 23.46 ± 27.45 | 28.83 ± 32.55 |
| Global health status/QoL: Baseline (n=57, 57) | 53.22 ± 22.03 | 54.97 ± 21.06 |
| Global health status/QoL: C2 D1 (n=49, 53) | 58.16 ± 20.38 | 59.59 ± 17.78 |
| Global health status/QoL: C3 D1 (n=45, 48) | 56.67 ± 20.07 | 59.72 ± 16.34 |
| Global health status/QoL: C4 D1 (n=37, 47) | 57.21 ± 18.02 | 57.80 ± 18.17 |
| Global health status/QoL: C5 D1 (n=32, 38) | 58.07 ± 21.94 | 61.84 ± 17.61 |
| Global health status/QoL: C6 D1 (n=29, 32) | 53.45 ± 17.75 | 60.94 ± 17.51 |
| Global health status/QoL: C7 D1 (n=28, 30) | 55.65 ± 20.17 | 58.61 ± 15.39 |
| Global health status/QoL: C8 D1 (n=22, 28) | 56.82 ± 17.18 | 60.71 ± 15.36 |
| Global health status/QoL: C9 D1 (n=18, 22) | 56.48 ± 23.14 | 64.40 ± 15.89 |
| Global health status/QoL: C10 D1 (n=17, 20) | 55.39 ± 17.91 | 62.50 ± 14.93 |
| Global health status/QoL: C11 D1 (n=15, 19) | 47.78 ± 19.02 | 63.60 ± 15.52 |
| Global health status/QoL: C12 D1 (n=10, 17) | 54.17 ± 19.35 | 63.73 ± 12.48 |
| Global health status/QoL: C13 D1 (n=8, 14) | 53.13 ± 19.89 | 58.33 ± 15.68 |
| Global health status/QoL: EOT (n=27, 38) | 49.38 ± 20.92 | 50.22 ± 21.62 |
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnoea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.
| Units on a scale | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Cough: Baseline (n=56, 59) | 37.50 ± 31.18 | 38.42 ± 24.62 |
| Cough: C2 D1 (n=50, 53) | 30.67 ± 24.13 | 30.19 ± 20.94 |
| Cough: C3 D1 (n=46, 47) | 28.98 ± 25.92 | 28.37 ± 23.03 |
| Cough: C4 D1 (n=37, 48) | 29.73 ± 25.80 | 27.08 ± 20.23 |
| Cough: C5 D1 (n=33, 38) | 22.22 ± 18.00 | 28.07 ± 23.92 |
| Cough: C6 D1 (n=29, 33) | 26.44 ± 24.20 | 26.26 ± 23.21 |
| Cough: C7 D1 (n=28, 29) | 25.00 ± 21.52 | 25.29 ± 24.65 |
| Cough: C8 D1 (n=22, 27) | 21.21 ± 19.37 | 19.75 ± 21.20 |
| Cough: C9 D1 (n=18, 23) | 20.37 ± 20.26 | 24.64 ± 25.06 |
| Cough: C10 D1 (n=17, 20) | 23.53 ± 25.73 | 21.67 ± 22.36 |
| Cough: C11 D1 (n=15, 19) | 24.44 ± 23.46 | 26.31 ± 23.78 |
| Cough: C12 D1 (n=10, 17) | 26.66 ± 14.05 | 29.41 ± 30.92 |
| Cough: C13 D1 (n=8, 14) | 33.33 ± 25.20 | 21.43 ± 21.11 |
| Cough: End of treatment (EOT) (n=26, 38) | 33.33 ± 21.08 | 33.33 ± 29.00 |
| Haemoptysis: Baseline (n=56, 59) | 2.98 ± 11.51 | 3.39 ± 10.16 |
| Haemoptysis: C2 D1 (n=50, 53) | 2.67 ± 9.13 | 1.89 ± 7.78 |
| Haemoptysis: C3 D1 (n=44, 47) | 0.76 ± 5.02 | 5.67 ± 14.44 |
| Haemoptysis: C4 D1 (n=36, 48) | 0.93 ± 5.56 | 3.47 ± 10.29 |
| Haemoptysis: C5 D1 (n=33, 38) | 1.01 ± 5.80 | 3.51 ± 12.94 |
| Haemoptysis: C6 D1 (n=29, 33) | 3.45 ± 13.64 | 3.03 ± 12.81 |
| Haemoptysis: C7 D1 (n=27, 29) | 0.00 ± 0.00 | 3.45 ± 10.33 |
| Haemoptysis: C8 D1 (n=22, 27) | 0.00 ± 0.00 | 1.23 ± 6.41 |
| Haemoptysis: C9 D1 (n=18, 23) | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Haemoptysis: C10 D1 (n=17, 20) | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Haemoptysis: C11 D1 (n=15, 19) | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Haemoptysis: C12 D1 (n=10, 17) | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Haemoptysis: C13 D1 (n=8, 14) | 4.17 ± 11.78 | 0.00 ± 0.00 |
| Haemoptysis: EOT (n=26, 38) | 0.00 ± 0.00 | 5.26 ± 16.49 |
| Dyspnoea: Baseline (n=56, 58) | 29.17 ± 20.60 | 31.42 ± 28.85 |
| Dyspnoea: C2 D1 (n=48, 53) | 29.86 ± 25.23 | 23.90 ± 21.51 |
| Dyspnoea: C3 D1 (n=45, 43) | 33.83 ± 22.09 | 20.41 ± 18.61 |
| Dyspnoea: C4 D1 (n=36, 45) | 32.10 ± 20.01 | 24.69 ± 21.57 |
| Dyspnoea: C5 D1 (n=33, 37) | 30.30 ± 21.21 | 23.12 ± 19.84 |
| Dyspnoea: C6 D1 (n=28, 31) | 35.32 ± 24.76 | 21.86 ± 18.70 |
| Dyspnoea: C7 D1 (n=27, 27) | 30.45 ± 25.52 | 20.16 ± 16.02 |
| Dyspnoea: C8 D1 (n=22, 26) | 24.75 ± 21.94 | 21.37 ± 16.61 |
| Dyspnoea: C9 D1 (n=18, 22) | 27.78 ± 29.83 | 18.69 ± 14.70 |
| Dyspnoea: C10 D1 (n=17, 19) | 28.76 ± 27.80 | 19.88 ± 15.08 |
| Dyspnoea: C11 D1 (n=15, 18) | 27.41 ± 24.80 | 19.75 ± 15.51 |
| Dyspnoea: C12 D1 (n=10, 17) | 23.33 ± 22.50 | 22.22 ± 19.25 |
| Dyspnoea: C13 D1 (n=8, 14) | 37.50 ± 31.95 | 16.67 ± 16.16 |
| Dyspnoea: EOT (n=25, 37) | 34.22 ± 23.33 | 33.63 ± 28.39 |
| Sore Mouth: Baseline (n=56, 58) | 3.57 ± 12.19 | 1.15 ± 6.13 |
| Sore Mouth: C2 D1 (n=51, 53) | 18.95 ± 26.88 | 9.43 ± 23.00 |
| Sore Mouth: C3 D1 (n=45, 47) | 18.52 ± 28.03 | 9.22 ± 21.65 |
| Sore Mouth: C4 D1 (n=37, 48) | 21.62 ± 31.64 | 8.33 ± 21.19 |
| Sore Mouth: C5 D1 (n=33, 38) | 23.23 ± 36.79 | 11.40 ± 23.60 |
| Sore Mouth: C6 D1 (n=28, 33) | 16.67 ± 30.77 | 6.06 ± 19.46 |
| Sore Mouth: C7 D1 (n=28, 29) | 17.86 ± 27.94 | 6.90 ± 16.38 |
| Sore Mouth: C8 D1 (n=22, 27) | 16.67 ± 30.43 | 3.70 ± 10.67 |
| Sore Mouth: C9 D1 (n=18, 23) | 9.26 ± 15.36 | 5.80 ± 16.37 |
| Sore Mouth: C10 D1 (n=17, 20) | 19.61 ± 33.46 | 10.00 ± 26.71 |
| Sore Mouth: C11 D1 (n=15, 19) | 22.22 ± 37.09 | 8.77 ± 24.45 |
| Sore Mouth: C12 D1 (n=10, 17) | 16.67 ± 23.57 | 7.84 ± 18.74 |
| Sore Mouth: C13 D1 (n=8, 14) | 25.00 ± 38.83 | 4.76 ± 12.10 |
| Sore Mouth: EOT (n=26, 38) | 8.97 ± 24.14 | 4.39 ± 13.80 |
| Dysphagia: Baseline (n=56, 59) | 6.55 ± 17.31 | 6.78 ± 14.88 |
| Dysphagia: C2 D1 (n=51, 53) | 11.76 ± 22.92 | 6.92 ± 17.73 |
| Dysphagia: C3 D1 (n=46, 47) | 13.77 ± 20.58 | 4.96 ± 11.99 |
| Dysphagia: C4 D1 (n=37, 48) | 9.91 ± 20.59 | 2.78 ± 9.31 |
| Dysphagia: C5 D1 (n=32, 38) | 12.50 ± 26.44 | 4.39 ± 11.42 |
| Dysphagia: C6 D1 (n=28, 33) | 13.10 ± 27.73 | 7.07 ± 16.15 |
| Dysphagia: C7 D1 (n=28, 28) | 11.90 ± 26.00 | 5.95 ± 15.85 |
| Dysphagia: C8 D1 (n=22, 27) | 16.67 ± 26.73 | 1.23 ± 6.41 |
| Dysphagia: C9 D1 (n=18, 23) | 9.26 ± 15.36 | 1.45 ± 6.95 |
| Dysphagia: C10 D1 (n=17, 20) | 21.57 ± 26.20 | 6.67 ± 17.44 |
| Dysphagia: C11 D1 (n=15, 19) | 24.44 ± 29.46 | 1.75 ± 7.65 |
| Dysphagia: C12 D1 (n=10, 17) | 6.67 ± 14.05 | 3.92 ± 16.17 |
| Dysphagia: C13 D1 (n=8, 14) | 20.83 ± 24.80 | 4.76 ± 17.82 |
| Dysphagia: EOT (n=26, 38) | 7.69 ± 21.72 | 7.89 ± 19.66 |
| Peripheral neuropathy: Baseline (n=56, 59) | 9.52 ± 19.81 | 15.25 ± 26.50 |
| Peripheral neuropathy: C2 D1 (n=51, 53) | 24.84 ± 30.44 | 33.96 ± 33.01 |
| Peripheral neuropathy: C3 D1 (n=46, 47) | 37.68 ± 34.15 | 34.75 ± 36.09 |
| Peripheral neuropathy: C4 D1 (n=37, 48) | 45.05 ± 37.86 | 38.19 ± 32.97 |
| Peripheral neuropathy: C5 D1 (n=33, 38) | 50.51 ± 39.19 | 42.11 ± 33.50 |
| Peripheral neuropathy: C6 D1 (n=29, 33) | 55.17 ± 39.11 | 52.53 ± 33.37 |
| Peripheral neuropathy: C7 D1 (n=28, 29) | 48.81 ± 37.93 | 54.02 ± 33.82 |
| Peripheral neuropathy: C8 D1 (n=22, 27) | 57.58 ± 40.08 | 50.62 ± 36.25 |
| Peripheral neuropathy: C9 D1 (n=17, 23) | 45.10 ± 40.73 | 56.52 ± 36.84 |
| Peripheral neuropathy: C10 D1 (n=17, 20) | 45.10 ± 42.40 | 48.33 ± 38.20 |
| Peripheral neuropathy: C11 D1 (n=14, 19) | 50.00 ± 42.87 | 49.12 ± 35.78 |
| Peripheral neuropathy: C12 D1 (n=9, 17) | 55.56 ± 40.83 | 54.90 ± 38.98 |
| Peripheral neuropathy: C13 D1 (n=8, 14) | 58.33 ± 42.73 | 47.62 ± 38.60 |
| Peripheral neuropathy: EOT (n=25, 38) | 37.33 ± 35.12 | 40.35 ± 38.87 |
| Alopecia: Baseline (n=56, 59) | 2.98 ± 11.51 | 2.26 ± 10.48 |
| Alopecia: C2 D1 (n=50, 53) | 69.33 ± 33.56 | 71.70 ± 32.29 |
| Alopecia: C3 D1 (n=46, 45) | 73.91 ± 37.13 | 68.89 ± 38.53 |
| Alopecia: C4 D1 (n=37, 45) | 65.77 ± 40.43 | 60.00 ± 42.40 |
| Alopecia: C5 D1 (n=33, 35) | 61.62 ± 44.19 | 64.76 ± 44.24 |
| Alopecia: C6 D1 (n=28, 32) | 69.05 ± 42.48 | 61.46 ± 45.68 |
| Alopecia: C7 D1 (n=28, 28) | 39.29 ± 46.31 | 40.48 ± 45.68 |
| Alopecia: C8 D1 (n=21, 27) | 42.86 ± 44.90 | 44.44 ± 48.92 |
| Alopecia: C9 D1 (n=18, 23) | 27.78 ± 43.16 | 31.88 ± 44.36 |
| Alopecia: C10 D1 (n=17, 20) | 31.37 ± 43.25 | 11.67 ± 29.17 |
| Alopecia: C11 D1 (n=14, 18) | 16.67 ± 36.40 | 16.67 ± 34.77 |
| Alopecia: C12 D1 (n=10, 17) | 13.33 ± 28.11 | 9.80 ± 28.30 |
| Alopecia: C13 D1 (n=8, 14) | 8.33 ± 23.57 | 7.14 ± 26.73 |
| Alopecia: EOT (n=26, 37) | 33.33 ± 42.16 | 27.03 ± 39.94 |
| Chest pain: Baseline (n=56, 59) | 23.81 ± 28.93 | 20.90 ± 25.45 |
| Chest pain: C2 D1 (n=51, 53) | 18.95 ± 27.69 | 10.06 ± 18.00 |
| Chest pain: C3 D1 (n=45, 47) | 14.81 ± 25.18 | 5.67 ± 12.66 |
| Chest pain: C4 D1 (n=36, 48) | 14.81 ± 24.49 | 9.03 ± 19.13 |
| Chest pain: C5 D1 (n=33, 38) | 11.11 ± 19.84 | 3.51 ± 10.37 |
| Chest pain: C6 D1 (n=28, 33) | 15.48 ± 21.24 | 1.01 ± 5.80 |
| Chest pain: C7 D1 (n=28, 28) | 11.90 ± 18.62 | 3.57 ± 10.50 |
| Chest pain: C8 D1 (n=22, 27) | 13.64 ± 16.77 | 3.70 ± 10.67 |
| Chest pain: C9 D1 (n=18, 23) | 12.96 ± 20.26 | 7.25 ± 14.06 |
| Chest pain: C10 D1 (n=17, 20) | 13.72 ± 16.91 | 8.33 ± 18.34 |
| Chest pain: C11 D1 (n=15, 19) | 24.44 ± 29.46 | 7.02 ± 13.96 |
| Chest pain: C12 D1 (n=10, 16) | 13.33 ± 17.21 | 2.08 ± 8.33 |
| Chest pain: C13 D1 (n=7, 14) | 19.05 ± 26.23 | 4.76 ± 12.10 |
| Chest pain: EOT (n=26, 37) | 30.77 ± 33.89 | 15.31 ± 24.34 |
| Arm/shoulder pain: Baseline (n=56, 59) | 20.83 ± 27.39 | 20.34 ± 29.04 |
| Arm/shoulder pain: C2 D1 (n=51, 53) | 20.91 ± 28.25 | 20.75 ± 24.66 |
| Arm/shoulder pain: C3 D1 (n=45, 47) | 14.81 ± 25.18 | 5.67 ± 12.66 |
| Arm/shoulder pain: C4 D1 (n=37, 47) | 18.92 ± 25.51 | 17.02 ± 30.19 |
| Arm/shoulder pain: C5 D1 (n=33, 38) | 14.14 ± 26.39 | 14.91 ± 26.51 |
| Arm/shoulder pain: C6 D1 (n=29, 33) | 16.09 ± 26.16 | 5.05 ± 12.14 |
| Arm/shoulder pain: C7 D1 (n=28, 29) | 15.48 ± 23.10 | 14.94 ± 22.86 |
| Arm/shoulder pain: C8 D1 (n=22, 26) | 16.67 ± 26.73 | 14.10 ± 19.26 |
| Arm/shoulder pain: C9 D1 (n=18, 23) | 14.81 ± 23.49 | 13.04 ± 19.43 |
| Arm/shoulder pain: C10 D1 (n=17, 20) | 13.73 ± 23.74 | 20.00 ± 27.36 |
| Arm/shoulder pain: C11 D1 (n=14, 19) | 26.19 ± 29.75 | 15.79 ± 23.22 |
| Arm/shoulder pain: C12 D1 (n=10, 17) | 23.33 ± 22.50 | 25.49 ± 32.34 |
| Arm/shoulder pain: C13 D1 (n=8, 14) | 20.83 ± 24.80 | 19.05 ± 25.20 |
| Arm/shoulder pain: EOT (n=26, 38) | 21.80 ± 33.92 | 23.68 ± 31.87 |
| Other pain: Baseline (n=52, 57) | 28.85 ± 32.36 | 25.15 ± 34.09 |
| Other pain: C2 D1 (n=49, 50) | 26.53 ± 28.85 | 32.67 ± 31.94 |
| Other pain: C3 D1 (n=46, 47) | 34.06 ± 31.81 | 23.40 ± 31.79 |
| Other pain: C4 D1 (n=36, 45) | 25.93 ± 27.73 | 28.15 ± 30.11 |
| Other pain: C5 D1 (n=32, 38) | 25.00 ± 29.33 | 26.32 ± 33.02 |
| Other pain: C6 D1 (n=28, 33) | 29.76 ± 26.20 | 27.27 ± 33.80 |
| Other pain: C7 D1 (n=28, 28) | 32.14 ± 35.70 | 35.71 ± 36.21 |
| Other pain: C8 D1 (n=22, 26) | 16.67 ± 28.64 | 25.64 ± 33.08 |
| Other pain: C9 D1 (n=15, 23) | 31.11 ± 34.43 | 31.88 ± 34.05 |
| Other pain: C10 D1 (n=16, 19) | 25.00 ± 28.55 | 22.81 ± 31.53 |
| Other pain: C11 D1 (n=14, 18) | 42.86 ± 33.15 | 25.93 ± 33.44 |
| Other pain: C12 D1 (n=10, 17) | 33.33 ± 27.22 | 27.45 ± 33.82 |
| Other pain: C13 D1 (n=8, 14) | 29.17 ± 27.82 | 26.19 ± 29.75 |
| Other pain: EOT (n=25, 37) | 34.67 ± 32.60 | 29.73 ± 36.67 |
| Medicine for pain: Baseline (n=37, 35) | 60.36 ± 29.23 | 66.67 ± 28.01 |
| Medicine for pain: C3 D1 (n=29, 24) | 65.52 ± 31.48 | 68.06 ± 31.82 |
| Medicine for pain: C4 D1 (n=19, 29) | 63.16 ± 26.98 | 72.41 ± 23.69 |
| Medicine for pain: C5 D1 (n=17, 22) | 70.59 ± 26.04 | 72.73 ± 22.15 |
| Medicine for pain: C6 D1 (n=16, 17) | 66.67 ± 29.81 | 72.55 ± 24.25 |
| Medicine for pain: C7 D1 (n=15, 14) | 75.56 ± 26.63 | 66.67 ± 29.24 |
| Medicine for pain: C8 D1 (n=13, 16) | 66.67 ± 27.22 | 75.00 ± 25.82 |
| Medicine for pain: C9 D1 (n=6, 14) | 72.23 ± 13.61 | 69.05 ± 20.52 |
| Medicine for pain: C10 D1 (n=10, 10) | 73.34 ± 14.05 | 60.00 ± 26.30 |
| Medicine for pain: C11 D1 (n=9, 9) | 48.15 ± 17.57 | 81.48 ± 17.57 |
| Medicine for pain: C12 D1 (n=6, 9) | 55.56 ± 17.22 | 70.37 ± 20.03 |
| Medicine for pain: C13 D1 (n=0, 0) | NA ± NA | NA ± NA |
| Medicine for pain: EOT (n=15, 19) | 60.00 ± 22.54 | 66.67 ± 29.40 |
| Medicine for pain: C2 D1 (n=30, 35) | 62.22 ± 22.72 | 71.43 ± 26.99 |
RNA expression profiles of genes which were associated with tumor growth, angiogenesis and metastases were collected and correlated with efficacy.
No measurements were reported for this outcome.
Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.
| Cells/milliliter (cells/mL) | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Baseline (n=39, 37) | 46815.38 ± 131531.755 | 16960.41 ± 25527.526 |
| C1 D15 (n=27, 29) | 11780.15 ± 13127.847 | 21882.41 ± 67578.781 |
| C2 D1 (n=32, 28) | 29229.09 ± 55724.997 | 40507.36 ± 82161.060 |
| C3 D1 (n=24, 30) | 19517.50 ± 19793.722 | 25215.70 ± 42932.747 |
| C4 D1 (n=20, 27) | 24556.05 ± 22434.011 | 41944.59 ± 70239.938 |
| C5 D1 (n=18, 23) | 28266.22 ± 39480.209 | 37468.13 ± 82647.380 |
| C7 D1 (n=11, 14) | 71770.91 ± 94182.032 | 36964.36 ± 60577.084 |
| C9 D1 (n=7, 7) | 58680.00 ± 78138.794 | 107978.14 ± 206314.489 |
| C11 D1 (n=6, 6) | 116620.83 ± 129577.280 | 120847.67 ± 140674.394 |
Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.
| Flourescent Intensity Unit (FIU) | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Baseline (pVEGFR2+) (n=50, 42) | 1936317.98 ± 1252665.900 | 1764577.67 ± 1331540.549 |
| C1 D15 (pVEGFR2+) (n=38, 37) | 1822095.74 ± 1678888.153 | 1810049.32 ± 1330590.809 |
| C2 D1 (pVEGFR2+) (n=41, 35) | 1767065.44 ± 1442193.213 | 2090673.60 ± 1659128.892 |
| C3 D1 (pVEGFR2+) (n=33, 34) | 1715569.39 ± 1515661.662 | 1578940.53 ± 1274415.109 |
| C4 D1 (pVEGFR2+) (n=25, 32) | 1472447.68 ± 970463.341 | 1815402.16 ± 1263516.725 |
| C5 D1 (pVEGFR2+) (n=24, 26) | 2208801.96 ± 3098289.400 | 1794843.58 ± 1458412.725 |
| C7 D1 (pVEGFR2+) (n=16, 16) | 1405048.00 ± 879770.893 | 1634128.00 ± 1443612.089 |
| C9 D1 (pVEGFR2+) (n=12, 11) | 2280989.75 ± 1050678.808 | 2283985.00 ± 1093158.760 |
| C11 D1 (pVEGFR2+) (n=10, 9) | 1828224.90 ± 1179020.490 | 2354939.11 ± 1116283.011 |
| Baseline (VEGFR2+) (n=50, 42) | 1694522.56 ± 1534520.504 | 1841618.36 ± 1300088.201 |
| C1 D15 (VEGFR2+) (n=38, 37) | 1634956.89 ± 1285333.248 | 1740268.05 ± 1444881.394 |
| C2 D1 (VEGFR2+) (n=41, 35) | 1597041.59 ± 865675.123 | 1444404.94 ± 1097875.465 |
| C3 D1 (VEGFR2+) (n=33, 34) | 1443986.61 ± 843071.909 | 1504595.71 ± 1163469.112 |
| C4 D1 (VEGFR2+) (n=25, 32) | 1181666.88 ± 673860.407 | 1259913.44 ± 765707.741 |
| C5 D1 (VEGFR2+) (n=24, 25) | 1371956.00 ± 948166.942 | 1447188.88 ± 885864.695 |
| C7 D1 (VEGFR2+) (n=16, 16) | 1028231.44 ± 495059.378 | 1317560.13 ± 720095.027 |
| C9 D1 (VEGFR2+) (n=12, 11) | 1485819.58 ± 953884.288 | 1476621.00 ± 1688887.819 |
| C11 D1 (VEGFR2+) (n=10, 9) | 1573298.80 ± 1152155.993 | 1332064.78 ± 668964.428 |
| Baseline (pPDGFRB+) (n=50, 42) | 1646702.34 ± 1482336.244 | 1734853.24 ± 1485338.326 |
| C1 D15 (pPDGFRB+) (n=38, 37) | 1253893.97 ± 894629.298 | 1599671.65 ± 1669690.889 |
| C2 D1 (pPDGFRB+) (n=41, 35) | 1395311.88 ± 1111766.454 | 1885684.31 ± 1356916.305 |
| C3 D1 (pPDGFRB+) (n=33, 34) | 1470448.94 ± 841336.398 | 1285439.44 ± 1083860.541 |
| C4 D1 (pPDGFRB+) (n=25, 32) | 1046445.72 ± 588769.375 | 1514713.97 ± 1150805.007 |
| C5 D1 (pPDGFRB+) (n=24, 26) | 2253114.67 ± 3314986.569 | 2299459.38 ± 5140939.706 |
| C7 D1 (pPDGFRB+) (n=16, 16) | 1380133.19 ± 1002147.826 | 2163313.88 ± 3720352.717 |
| C9 D1 (pPDGFRB+) (n=12, 11) | 2172539.75 ± 2323386.087 | 2225289.18 ± 1126401.528 |
| C11 D1 (pPDGFRB+) (n=10, 9) | 1580028.90 ± 927582.364 | 3127640.22 ± 2817719.865 |
| Baseline (PDGFRB+) (n=50, 42) | 1775826.12 ± 1485762.540 | 3176459.69 ± 3222201.986 |
| C1 D15 (PDGFRB+) (n=38, 37) | 1589914.37 ± 985828.939 | 1819988.05 ± 1807664.991 |
| C2 D1 (PDGFRB+) (n=41, 35) | 1840677.73 ± 1315688.806 | 1586256.17 ± 1092406.544 |
| C3 D1 (PDGFRB+) (n=33, 34) | 1690163.33 ± 1064816.034 | 1518360.71 ± 1286285.813 |
| C4 D1 (PDGFRB+) (n=25, 32) | 1288624.64 ± 641546.254 | 1408366.91 ± 1013859.813 |
| C5 D1 (PDGFRB+) (n=24, 26) | 1309639.50 ± 975890.557 | 1364500.50 ± 1058758.211 |
| C7 D1 (PDGFRB+) (n=16, 16) | 1049351.00 ± 587546.139 | 1287039.25 ± 922009.811 |
| C9 D1 (PDGFRB+) (n=12, 11) | 1666413.67 ± 1465165.325 | 1625161.64 ± 1467355.491 |
| C11 D1 (PDGFRB+) (n=10, 9) | 1533606.00 ± 1258733.501 | 1959067.11 ± 1973194.943 |
Plasma concentrations of soluble proteins (soluble- stem-cell factor receptor (sKIT) vascular endothelial growth factor \[VEGF\], and vascular endothelial growth factor receptor-2 \[VEGFR2\], VEGFR3) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.
| Picogram/mL (pg/mL) | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Baseline (SKIT) (n=52, 47) | 49740.29 ± 16998.69 | 49544.15 ± 14803.62 |
| C1 D15 (SKIT) (n=42, 36) | 53095.48 ± 18233.85 | 55801.39 ± 22058.63 |
| C2 D1 (SKIT) (n=41, 43) | 52979.39 ± 18018.73 | 55729.65 ± 21476.66 |
| C3 D1 (SKIT) (n=40, 38) | 53817.75 ± 19638.72 | 65634.14 ± 27097.91 |
| C4 D1 (SKIT) (n=32, 38) | 56961.41 ± 20828.07 | 72671.32 ± 33207.22 |
| C5 D1 (SKIT) (n=27, 34) | 58305.00 ± 20311.85 | 68677.21 ± 30073.83 |
| C7 D1 (SKIT) (n=18, 23) | 50701.11 ± 17927.98 | 75547.61 ± 24458.54 |
| C9 D1 (SKIT) (n=12, 16) | 48680.42 ± 14791.32 | 65990.78 ± 17003.08 |
| C11 D1 (SKIT) (n=11, 13) | 49251.82 ± 19469.45 | 66920.38 ± 12261.25 |
| Baseline (VEGF) (n=50, 48) | 95.14 ± 66.60 | 121.83 ± 141.22 |
| C1 D15 (VEGF) (n=40, 37) | 117.08 ± 98.05 | 287.19 ± 171.77 |
| C2 D1 (VEGF) (n=39, 43) | 127.46 ± 128.06 | 324.33 ± 153.65 |
| C3 D1 (VEGF) (n=39, 38) | 148.06 ± 159.80 | 368.23 ± 151.20 |
| C4 D1 (VEGF) (n=30, 38) | 197.16 ± 282.49 | 405.13 ± 173.86 |
| C5 D1 (VEGF) (n=25, 34) | 184.77 ± 175.32 | 400.16 ± 165.69 |
| C7 D1 (VEGF) (n=18, 23) | 226.62 ± 202.53 | 433.30 ± 172.14 |
| C9 D1 (VEGF) (n=12, 16) | 273.17 ± 207.22 | 422.38 ± 157.76 |
| C11 D1 (VEGF) (n=11, 13) | 339.86 ± 303.71 | 449.92 ± 144.50 |
| Baseline (VEGFR2) (n=52, 48) | 9587.31 ± 1570.27 | 9995.00 ± 2185.61 |
| C1 D15 (VEGFR2) (n=42, 37) | 7828.10 ± 1959.39 | 10781.35 ± 2311.90 |
| C2 D1 (VEGFR2) (n=41, 43) | 7477.80 ± 2146.89 | 10330.00 ± 2511.23 |
| C3 D1 (VEGFR2) (n=40, 38) | 7058.50 ± 2037.12 | 10129.47 ± 2244.65 |
| C4 D1 (VEGFR2) (n=32, 38) | 6885.94 ± 1754.19 | 9934.21 ± 1785.78 |
| C5 D1 (VEGFR2) (n=27, 34) | 6565.93 ± 1755.75 | 10140.59 ± 2056.40 |
| C7 D1 (VEGFR2) (n=18, 23) | 6401.11 ± 2360.24 | 10339.57 ± 1897.95 |
| C9 D1 (VEGFR2) (n=12, 16) | 6291.67 ± 2235.24 | 9421.25 ± 2446.42 |
| C11 D1 (VEGFR2) (n=11, 13) | 5696.36 ± 2724.57 | 9222.31 ± 2727.04 |
| Baseline (VEGFR3) (n=52, 48) | 44390.77 ± 75118.17 | 24718.33 ± 12494.07 |
| C1 D15 (VEGFR3) (n=42, 37) | 33684.29 ± 52617.02 | 17693.51 ± 9679.53 |
| C2 D1 (VEGFR3) (n=41, 43) | 35780.49 ± 68287.68 | 17798.37 ± 9710.23 |
| C3 D1 (VEGFR3) (n=40, 38) | 34147.00 ± 74220.30 | 15901.32 ± 8062.41 |
| C4 D1 (VEGFR3) (n=32, 38) | 19730.94 ± 9237.69 | 16307.37 ± 7409.61 |
| C5 D1 (VEGFR3) (n=27, 34) | 17452.59 ± 8614.99 | 16381.47 ± 6707.41 |
| C7 D1 (VEGFR3) (n=18, 23) | 17896.67 ± 8360.82 | 15626.30 ± 8873.31 |
| C9 D1 (VEGFR3) (n=12, 16) | 21449.17 ± 12806.75 | 14733.44 ± 6441.61 |
| C11 D1 (VEGFR3) (n=11, 13) | 22332.73 ± 12408.37 | 16048.46 ± 7064.47 |
UGT1A1 an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib + Paclitaxel + Carboplatin | — | 31/58 (53.4%) | 54/58 (93.1%) |
| Bevacizumab + Paclitaxel + Carboplatin | — | 19/59 (32.2%) | 58/59 (98.3%) |
| Event | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| Disease progressionGeneral disorders | 7/58 | 3/59 |
| DehydrationMetabolism and nutrition disorders | 4/58 | 0/59 |
| AstheniaGeneral disorders | 3/58 | 0/59 |
| Myocardial infarctionCardiac disorders | 2/58 | 0/59 |
| SepsisInfections and infestations | 2/58 | 0/59 |
| NeutropeniaBlood and lymphatic system disorders | 1/58 | 2/59 |
| OesophagitisGastrointestinal disorders | 0/58 | 2/59 |
| FatigueGeneral disorders | 1/58 | 2/59 |
| Lower respiratory tract infectionInfections and infestations | 0/58 | 2/59 |
| AnaemiaBlood and lymphatic system disorders | 1/58 | 0/59 |
| Event | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 27/58 | 20/59 |
| AlopeciaSkin and subcutaneous tissue disorders | 21/58 | 27/59 |
| Decreased appetiteMetabolism and nutrition disorders | 25/58 | 12/59 |
| HypertensionVascular disorders | 24/58 | 25/59 |
| FatigueGeneral disorders | 20/58 | 22/59 |
| NauseaGastrointestinal disorders | 21/58 | 19/59 |
| NeutropeniaBlood and lymphatic system disorders | 18/58 | 15/59 |
| AstheniaGeneral disorders | 17/58 | 6/59 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 17/58 | 15/59 |
| ConstipationGastrointestinal disorders | 16/58 | 17/59 |
Intent-to-treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.
| Age, Customized(Participants) | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| Less than 18 years | 0 | 0 | 0 |
| 18 to 44 years | 1 | 2 | 3 |
| 45 to 64 years | 33 | 44 | 77 |
| Greater than or equal to 65 years | 24 | 14 | 38 |
| Sex: Female, Male(Participants) | Axitinib + Paclitaxel + Carboplatin | Bevacizumab + Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| Female | 22 | 23 | 45 |
| Male | 36 | 37 | 73 |
The record gives a start of Apr 2008, a primary completion of Apr 2011 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 1 year 1 month after primary completion. A results delay was requested in Feb 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib
Carcinoma, Non-Small-Cell Lung →